Actively Recruiting
Evaluating Hetrombopag Olamine Tablets Versus Placebo for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors A Phase III Randomized, Double-Blind, Multi-Center Trial
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2026-10-01
150
Participants Needed
51
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of Hetrombopag Olamine Tablets compared to a placebo in patients with thrombocytopenia caused by chemotherapy. The study focuses on patients who have solid tumors and experience low platelet counts due to chemotherapy treatment. This phase III trial is conducted by Jiangsu HengRui Medicine Co., Ltd. and aims to better understand treatment options for chemotherapy-induced thrombocytopenia. Participants receive treatments in two parts in Part A, all participants are given Hetrombopag Olamine. In Part B, participants are randomly assigned to receive either Hetrombopag Olamine or a matching placebo. Treatments are given during chemotherapy cycles that occur every 14 or 21 days. The study includes monitoring over approximately 3 years to assess platelet counts and the need for rescue therapies. During the study, participants undergo regular monitoring of platelet levels, safety labs, and vital signs. Researchers track whether participants maintain platelet counts sufficient to continue chemotherapy without delay or modification. Outcomes include measuring platelet count improvements, bleeding events, and adverse reactions. The overall participation lasts up to about three years, with ongoing assessment of chemotherapy cycle completion and treatment safety.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)
Research Team
B
Brian Yu, MD
J
Junye Xiong, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here